Differential Expression Of The Regulated Catecholamine Secretory Pathway In Different Hereditary Forms Of Pheochromocytoma.
G. Eisenhofer, Thanh-Truc Huynh, A. Elkahloun, J. Morris, G. Bratslavsky, W. Linehan, Z. Zhuang, B. Balgley, C. S. Lee, M. Mannelli, J. Lenders, S. Bornstein, K. Pacak
Published 2008 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Pheochromocytomas in patients with von Hippel-Lindau (VHL) syndrome and multiple endocrine neoplasia type 2 (MEN 2) differ in the types and amounts of catecholamines produced and the resulting signs and symptoms. We hypothesized the presence of different processes of catecholamine release reflecting differential expression of components of the regulated secretory pathway among the two types of hereditary tumors. Differences in catecholamine secretion from tumors in patients with VHL syndrome (n = 47) and MEN 2 (n = 32) were examined using measurements of catecholamines in tumor tissue, urine, and plasma, the last of which was under baseline conditions in all subjects and in a subgroup of patients who received intravenous glucagon to provoke catecholamine release. Microarray and proteomics analyses, quantitative PCR, and Western blotting were used to assess expression of tumor tissue secretory pathway components. The rate constant for baseline catecholamine secretion was 20-fold higher in VHL than in MEN 2 tumors (0.359 +/- 0.094 vs. 0.018 +/- 0.009 day(-1)), but catecholamine release was responsive only to glucagon in MEN 2 tumors. Compared with tumors from MEN 2 patients, those from VHL patients were characterized by reduced expression of numerous components of the regulated secretory pathway (e.g., SNAP25, syntaxin, rabphilin 3A, annexin A7, calcium-dependent secretion activator). The mutation-dependent differences in expression of secretory pathway components indicate a more mature regulated secretory pathway in MEN 2 than VHL tumors. These data provide a unique mechanistic link to explain how variations in the molecular machinery governing exocytosis may contribute to clinical differences in the secretion of neurotransmitters or hormones and the subsequent presentation of a disease.
This paper references
Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.
G. Eisenhofer (1999)
A New Binding Motif for the Transcriptional Repressor REST Uncovers Large Gene Networks Devoted to Neuronal Functions
S. J. Otto (2007)
Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome.
S. Cleary (2007)
TURNOVER AND METABOLISM OF CATECHOLAMINES IN PATIENTS WITH PHEOCHROMOCYTOMA.
J. Crout (1964)
Sulfation and constitutive secretion of dopamine beta-hydroxylase from rat pheochromocytoma (PC12) cells.
E. M. McHugh (1985)
Norepinephrine and epinephrine secretion from a clinically epinephrine-secreting pheochromocytoma.
S. Aronoff (1980)
A role for the transcriptional repressor REST in maintaining the phenotype of neurosecretory-deficient PC12 cells.
A. Pance (2006)
A model for random sampling and estimation of relative protein abundance in shotgun proteomics.
Hongbin Liu (2004)
The synaptic vesicle cycle
T. Südhof (2004)
Expression of the neurosecretory process in PC12 cells is governed by REST.
R. Dalessandro (2008)
Mechanisms in histamine-mediated secretion from adrenal chromaffin cells.
P. Marley (2003)
Sympathetic nerve function--assessment by radioisotope dilution analysis.
G. Eisenhofer (2005)
Symptoms of pheochromocytoma, with particular reference to headache, correlated with catecholamine production.
J. Lance (1976)
The transcriptional repressor REST is a critical regulator of the neurosecretory phenotype.
Alexander W. Bruce (2006)
Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans
D. Goldstein (2003)
Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B.
F. M. Brouwers (2007)
Evaluation of confidence and reproducibility in quantitative proteomics performed by a capillary isoelectric focusing‐based proteomic platform coupled with a spectral counting approach
B. Balgley (2008)
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase.
G. Eisenhofer (1986)
Secretory granule exocytosis.
R. Burgoyne (2003)
Ultrastructural and biochemical characterization of catecholamine release mechanisms in cultured human pheochromocytoma cells.
Y. Chou (1998)
Core proteins of the secretory machinery.
T. Lang (2008)
Gene expression profiling of benign and malignant pheochromocytoma.
F. M. Brouwers (2006)
Human pheochromocytomas, but not adrenal medulla, express glucagon-receptor gene and possess an in vitro secretory response to glucagon
G. Albertin (2001)
Pheochromocytoma: the expanding genetic differential diagnosis.
Jennifer Bryant (2003)
Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
S. Cleary (2007)
Genetic ablation of the t-SNARE SNAP-25 distinguishes mechanisms of neuroexocytosis
P. Washbourne (2002)
Regulation of Membrane Fusion in Synaptic Excitation-Secretion Coupling: Speed and Accuracy Matter
S. Wojcik (2007)
Clinical and Experimental Pheochromocytoma
F. Messerli (1997)
Genetic testing in pheochromocytoma or functional paraganglioma.
L. Amar (2005)
Comprehensive yeast proteome analysis using a capillary isoelectric focusing-based multidimensional separation platform coupled with ESI-MS/MS.
W. Wang (2007)
Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
Thanh-Truc Huynh (2005)
Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome.
G. Eisenhofer (2004)
Pheochromocytoma: Diagnosis, Localization, and Treatment
K. Pacak (2007)
The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma
Y. Ito (2005)
Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes.
Alexander W. Bruce (2004)
Physiological aspects of exocytosis in chromaffin cells of the adrenal medulla.
D. Aunis (1999)
Altered regulation of calcium channels and exocytosis in single human pheochromocytoma cells
J. Hernández-Guijo (2000)
Real time quantitative PCR.
C. A. Heid (1996)
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
H. P. Neumann (2004)
Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes.
G. Eisenhofer (2001)
This paper is referenced by
Pheochromocytoma and paraganglioma: genotype versus anatomic location as determinants of tumor phenotype
Stephanie M J Fliedner (2017)
MEK/ERK cascade controls neuronal functioning by phosphorylation of different proteins such as transcription factors and enzymes as well as motor and exocytosis proteins
Mechanisms of Regulation of Vasopressinergic Neurons in the Hypothalamus of Rats Predisposed to Audiogenic Epilepsy
E. Gorbacheva (2019)
ERK1/2 inhibition increases dopamine release from differentiated PC12 cells
D. V. Zosen (2018)
Annexin 7 in the Regulation of Gastric Acid Secretion
Venkanna Pasham (2013)
Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement
W. Young (2017)
Inhibition of ERK1/2 signaling prevents epileptiform behavior in rats prone to audiogenic seizures.
Margarita V Glazova (2015)
Surgery: Risks of hemodynamic instability in pheochromocytoma
Graeme Eisenhofer (2010)
A study on the stability of urinary free catecholamines and free methyl-derivatives at different pH, temperature and time of storage
Norman Bryson Roberts (2010)
Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype
V. Amodru (2017)
Cement-augmented dorsal instrumentation of the spine as a safe adjunct to the multimodal management of metastatic pheochromocytoma: a case report
D. Rittirsch (2012)
Modern Surgical Management of Familial and Sporadic Parathyroid and Adrenal Disorders
A. Scholten (2013)
Blood Pressure Profile, Catecholamine Phenotype and Target Organ Damage in Pheochromocytoma/Paraganglioma.
Ondřej Petrák (2019)
Integrative analysis of neuroblastoma and pheochromocytoma genomics data
P. Szabó (2012)
Pheochromocytoma and abdominal paraganglioma.
J. Renard (2011)
PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.
M. Currás-Freixes (2017)
Influence of annexin A7 on insulin sensitivity of cellular glucose uptake
D. Luo (2014)
Pheochromocytoma and Multiple Endocrine Neoplasia
Claudia E. Reusch (2015)
Genetics of Pheochromocytoma and Paraganglioma
Bruna Babic (2017)
Characteristics of the Functional State of the Hypothalamo-Hypophyseal-Adrenocortical System in Krushinskii–Molodkina Rats
E. Gorbacheva (2020)
Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma
Jyotsna U. Rao (2013)
Developmentally Regulated Ca2+-Dependent Activator Protein for Secretion 2 (CAPS2) is Involved in BDNF Secretion and is Associated with Autism Susceptibility
T. Sadakata (2009)
von Hippel-Lindau Disease-Associated Pheochromocytoma : Epidemiology , Clinical Characteristics , and Screening and Surveillance Protocols in Japan
Masahiro Yao (2014)
Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.
G. Eisenhofer (2011)
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.
G. Eisenhofer (2011)
Genotype-specific differences in the metabolic profile of pheochromocytoma and paraganglioma: biomarkers, imaging and metastatic potential
Jyotsna Rao (2017)
New targets and therapeutic approaches for endocrine malignancies.
M. Fassnacht (2009)
Hemodynamic instability during resection of pheochromocytoma in MEN versus non-MEN patients.
Anouk Scholten (2011)
Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
Y. Aita (2012)
Genotype-Speci fi c Abnormalities in Mitochondrial Function Associate with Distinct Pro fi les of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma
Jyotsna U. Rao (2013)
Role des microARNs dans le controle de la voie de la sécrétion régulée dans les phéochromocytomes
A. Quillet (2018)
Diagnosing phaeochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging
L. Amar (2015)See more